JP2007533752A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533752A5
JP2007533752A5 JP2007509585A JP2007509585A JP2007533752A5 JP 2007533752 A5 JP2007533752 A5 JP 2007533752A5 JP 2007509585 A JP2007509585 A JP 2007509585A JP 2007509585 A JP2007509585 A JP 2007509585A JP 2007533752 A5 JP2007533752 A5 JP 2007533752A5
Authority
JP
Japan
Prior art keywords
phenyl
thiophen
thiazol
amino
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007509585A
Other languages
English (en)
Japanese (ja)
Other versions
JP4879165B2 (ja
JP2007533752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/013386 external-priority patent/WO2005103022A1/en
Publication of JP2007533752A publication Critical patent/JP2007533752A/ja
Publication of JP2007533752A5 publication Critical patent/JP2007533752A5/ja
Application granted granted Critical
Publication of JP4879165B2 publication Critical patent/JP4879165B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007509585A 2004-04-20 2005-04-20 メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体 Expired - Fee Related JP4879165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56388204P 2004-04-20 2004-04-20
US60/563,882 2004-04-20
PCT/US2005/013386 WO2005103022A1 (en) 2004-04-20 2005-04-20 Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators

Publications (3)

Publication Number Publication Date
JP2007533752A JP2007533752A (ja) 2007-11-22
JP2007533752A5 true JP2007533752A5 (enExample) 2011-09-01
JP4879165B2 JP4879165B2 (ja) 2012-02-22

Family

ID=34971867

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007509585A Expired - Fee Related JP4879165B2 (ja) 2004-04-20 2005-04-20 メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体

Country Status (12)

Country Link
US (1) US7820704B2 (enExample)
EP (1) EP1753735A1 (enExample)
JP (1) JP4879165B2 (enExample)
CN (1) CN1946703A (enExample)
AU (1) AU2005236055B2 (enExample)
BR (1) BRPI0510095A (enExample)
CA (1) CA2562075C (enExample)
IL (1) IL178597A0 (enExample)
MX (1) MXPA06012130A (enExample)
NZ (1) NZ550114A (enExample)
WO (1) WO2005103022A1 (enExample)
ZA (1) ZA200608225B (enExample)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521830A1 (en) * 2003-04-09 2004-10-21 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
DK1763517T3 (da) * 2004-06-28 2011-06-06 Hoffmann La Roche Pyrimidinderivater som 11beta-HSD1-inhibitorer
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0712144A2 (pt) * 2006-06-01 2012-01-24 Hoffmann La Roche compostos, processo apra a sua preparação, composição farmacêutica que compreende os mesmos, seu uso e método para o tratamento e/ou profilaxia de enfermidades
WO2008011191A1 (en) * 2006-07-21 2008-01-24 Replidyne, Inc. Antibacterial heterocyclic ureas
US7994338B2 (en) 2006-08-16 2011-08-09 The J. David Gladstone Institutes Small molecule inhibitors of kynurenine-3-monooxygenase
EP2420494B1 (en) 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
WO2009015208A1 (en) * 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial amide and sulfonamide substituted heterocyclic urea compounds
WO2009015193A1 (en) * 2007-07-23 2009-01-29 Replidyne, Inc. Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds
DK2212297T3 (da) 2007-10-12 2011-09-05 Ingenium Pharmaceuticals Gmbh Inhibitorer af proteinkinaser
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
DE102008019838A1 (de) * 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
CA2731323A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
EP2320738A4 (en) * 2008-08-29 2011-08-24 Transtech Pharma Inc SUBSTITUTED AMINOTHIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
EP2440519A1 (en) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
AU2010341229A1 (en) 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
WO2011076734A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2011076732A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
CN102834380B (zh) 2010-03-10 2015-04-01 阿斯利康公司 蛋白激酶的抑制剂
ES2742195T3 (es) 2010-03-12 2020-02-13 Omeros Corp Inhibidores de PDE10 y composiciones y métodos relacionados
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20130143927A1 (en) * 2011-06-10 2013-06-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR101742954B1 (ko) * 2012-05-31 2017-06-02 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체
WO2014066304A1 (en) * 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
WO2014074365A1 (en) * 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2014121055A2 (en) * 2013-02-04 2014-08-07 Janssen Pharmaceutica Nv Flap modulators
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Flap調節劑
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
US9708344B2 (en) 2014-06-03 2017-07-18 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
MX394388B (es) * 2015-05-15 2025-03-21 Aurigene Discovery Tech Ltd Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma
WO2016205304A1 (en) * 2015-06-16 2016-12-22 Signal Pharmaceuticals, Llc Methods of treatment using substituted diaminopyrimidyl compounds
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
CN107382902B (zh) * 2016-05-17 2022-08-12 华东理工大学 噻唑类衍生物及其应用
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3472167T3 (pl) 2016-06-20 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
FI4219492T3 (fi) 2018-05-11 2025-02-17 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
EP3846793B1 (en) * 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN114105902B (zh) * 2018-12-28 2023-11-03 中山大学 噻唑苯甲酰胺衍生物及其在制备抗骨质疏松药物中的应用
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US20230167078A1 (en) 2020-04-24 2023-06-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN112209886A (zh) * 2020-11-09 2021-01-12 沈阳药科大学 2-(3-氰基-4-烷氧基)苯基嘧啶衍生物及其制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2607369B2 (ja) 1987-02-20 1997-05-07 興和株式会社 新規な複素環化合物
US5502025A (en) * 1987-08-13 1996-03-26 Monsanto Company Safening herbicidal pyrazolylsulfonylureas
YU48319B (sh) 1988-08-01 1998-05-15 Monsanto Company Bezbednosni herbicidni derivati benzoeve kiseline
US5201933A (en) 1988-08-01 1993-04-13 Monsanto Company Safening herbicidal benzoic acid derivatives
FR2656610B1 (fr) * 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
JPH0532662A (ja) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
TW311136B (enExample) * 1990-11-30 1997-07-21 Otsuka Pharma Co Ltd
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1993015060A1 (fr) 1992-01-22 1993-08-05 Nissan Chemical Industries, Ltd. Derive de pyrazole substitue et bactericide agrohorticole
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
US6310034B1 (en) * 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
JPH07149745A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な2−アミノチアゾール誘導体
US5627131A (en) * 1995-01-09 1997-05-06 Zeneca Limited Herbicidal compositions of 4-benzoylisoxazole and antidotes therefor
US5766877A (en) * 1996-05-10 1998-06-16 Amgen Inc. Genes encoding art, an agouti-related transcript
WO1997047299A1 (en) 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6011048A (en) * 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
WO1999050295A2 (en) 1998-03-30 1999-10-07 Gryphon Sciences Agouti-related protein analogs and methods of use
US6689873B1 (en) * 1998-04-29 2004-02-10 Merck & Co., Inc. Nucleic acid encoding rat agouti related protein
CN1308618A (zh) 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的噁唑芳基-羧酸
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999058514A1 (en) 1998-05-12 1999-11-18 American Home Products Corporation (2-acylaminothiazole-4-yl)acetic acid derivatives
GB9818666D0 (en) 1998-08-27 1998-10-21 Rhone Poulenc Agriculture New herbicidal method
US6303749B1 (en) * 1999-01-29 2001-10-16 Amgen Inc. Agouti and agouti-related peptide analogs
EP2308833A3 (en) * 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20040132788A1 (en) * 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
IL153688A0 (en) * 2000-06-28 2003-07-06 Teva Pharma Carvedilol
CA2414461A1 (en) * 2000-06-29 2002-01-10 Abbott Laboratories Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
EP1435951B1 (en) * 2001-10-12 2006-01-18 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the tretment of obesity
SI1446394T1 (sl) 2001-11-08 2007-04-30 Ortho Mcneil Pharm Inc Novi 1,2,4-tiadiazolni derivati kot modulatorji melanokortinskega receptorja
US7163952B2 (en) * 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
US20030158199A1 (en) * 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
WO2003068738A1 (en) * 2002-02-11 2003-08-21 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
DE60316411T2 (de) * 2002-02-28 2008-06-12 F. Hoffmann-La Roche Ag Thiazolderivate als npy-rezeptorantagonisten
UA79755C2 (en) * 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
CA2488725A1 (en) 2002-07-03 2004-01-15 Su Qian Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism
BR0313278A (pt) * 2002-08-07 2005-07-05 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos
CA2521830A1 (en) 2003-04-09 2004-10-21 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬

Similar Documents

Publication Publication Date Title
JP2007533752A5 (enExample)
JP2005528348A5 (enExample)
JP2004532209A5 (enExample)
JP2014240402A5 (enExample)
JP2009529041A5 (enExample)
JP2007016035A5 (enExample)
RU2012132692A (ru) Новые ингибиторы s-нитрозоглутатионредуктазы
JP2009502743A5 (enExample)
JP2006525364A5 (enExample)
JP2005511547A5 (enExample)
JP2019142964A5 (enExample)
JP2017214387A5 (enExample)
JPH10287651A5 (enExample)
NO20084634L (no) Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav
JP2010507590A5 (enExample)
JP2005522492A5 (enExample)
JP2008513510A5 (enExample)
JP2009539874A5 (enExample)
JP2009501704A5 (enExample)
WO2006027798A3 (en) A process for preparation of an antidepressant compound
WO2005000243A3 (en) The polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid
JP2002526530A5 (enExample)
JP2010527364A5 (enExample)
JP2008546652A5 (enExample)
JP2004525912A5 (enExample)